Kymera Therapeutics (NASDAQ: KYMR) reported Q3 EPS of ($0.82), $0.01 better than the analyst estimate of ($0.83). Revenue for the quarter came in at $3.74 million versus the consensus estimate of $10.34 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.